Recombinant Proteins iso9001 ISO13485
 > 【IGF-I】重组蛋白信息


英文名称:Insulin-like growth factor I
靶点别称:IGF-I,Insulin-Like Growth Factor IB,Insulin-Like Growth Factor I,Somatomedin C,IGFI,IGF1A,IGF,IBP1,MGF,Mechano growth factor,IGF1,Insulin Like Growth Factor 1,Insulin-Like Growth Factor 1 (Somatomedin C),Somatomedin-C


货号 物种 产品描述 蛋白结构 纯度 活性
Human IGF-I Protein,N-Fc Tag,HEK293 expressed

IGF-I 分子别名

IGF-I,IGF1A,somatomedin C,MGF

IGF-I 分子背景

Insulin-like growth factor 1 (IGF-1) is also known as somatomedin C, IGF1A, IGFI, sulfation factor, and is a hormone similar in molecular structure to insulin. It plays an important role in childhood growth and continues to have anabolic effects in adults. A synthetic analog of IGF-1, mecasermin is used for the treatment of growth failure. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges. IGF-1 has a molecular weight of 7649 daltons. IGF-1 is produced primarily by the liver as an endocrine hormone as well as in target tissues in a paracrine/autocrine fashion. IGF-1 binds to at least two cell surface receptors: the Insulin-like growth factor 1 receptor, abbreviated as "IGF1R", and the insulin receptor. The IGF-1 receptor seems to be the "physiologic" receptor - it binds IGF-1 at significantly higher affinity than the IGF-1 that is bound to the insulin receptor. Like the insulin receptor, the IGF-1 receptor is a receptor tyrosine kinase - meaning it signals by causing the addition of a phosphate molecule on particular tyrosines. Its primary action is mediated by binding to its specific receptor IGF1R, present on many cell types in many tissues. Binding to the IGF1R, a receptor tyrosine kinase, initiates intracellular signaling; IGF-1 is one of the most potent natural activators of the AKT signaling pathway, a stimulator of cell growth and proliferation, and a potent inhibitor of programmed cell death. Insulin-like growth factor 1 has been shown to bind and interact with all the IGF-1 Binding Proteins (IGFBPs), of which there are six (IGFBP1-6). Specific references are provided for interactions with IGFBP3, IGFBP4 and IGFBP7.

IGF-I 参考文献


英文名称 研发代码 研发阶段 公司 适应症 临床试验
HF-0299 NPC-01; HF-0299 临床一期 Ltt Institute 痛经, 神经痛 详情
Dusigitumab MEDI-573 临床二期 Medimmune Llc 肿瘤, 乳腺癌, 肝细胞癌 详情
Xentuzumab BI-836845 临床二期 勃林格殷格翰 肿瘤, 去势抵抗性前列腺肿瘤, 前列腺癌, 乳腺癌, 非小细胞肺癌 详情